Chronic hepatitis B virus infected participants responding to prior BRII-179 treatment achieved higher rate of sustained hepatitis B virus surface antigen loss on elebsiran plus peginterferon-alfa: Follow-up data from ENSURE study

Conference Reports for NATAP

The Liver Meeting
AASLD 2025
Washington, D.C.
November 7-11, 2025


Chronic hepatitis B virus infected participants responding to prior BRII-179 treatment achieved higher rate of sustained hepatitis B virus surface antigen loss on elebsiran plus peginterferon-alfa: Follow-up data from ENSURE study

	AASLD 2025 Nov 7-11 Wash DC Grace Lai-Hung Wong1